San Diego-based Beacon Discovery has added square footage and employees following partnership deals.
San Diego’s SGI-DNA, a spinout of Synthetic Genomics, has named life sciences veteran Todd Nelson as CEO.
PHARMA: Heron’s Anesthetic Aims to Reduce Opioid Use
Heron Therapeutics is now turning its attention toward commercialization of its postoperative anesthetic, riding a regulatory environment that appears to be itching for opioid alternatives.
San Diego-based Adamis Pharmaceuticals, which makes an allergy syringe, has signed over commercial rights to a division of Novartis.
DEVICES: Multipronged Plan Improves Earnings Trajectory
DJO Global CEO Brady Shirley likened the company’s business transformation plan to a knee surgery: short-term pain for long-term gain.
Mergers: Pharma Must Consider Many Factors in Buy
Earlier this month, an executive from New Jersey-based Celgene blamed Receptos, a San Diego firm that it bought, for a major regulatory setback.
San Diego-based Gossamer Bio entered into an agreement to develop and commercialize compounds from Cincinnati’s Aerpio Pharmaceuticals, in a deal worth as much as $420 million.
An associate professor with Salk Institute was named one of three winners of the Blavatnik National Awards for Young Scientists, which comes with $250,000 for her pioneering bacteria research.
John Farnam of Receptos has been named as COO of Kura Oncology. He will start in the newly created position July 1.
Calibr, a nonprofit affiliated with Scripps Research, announced a collaboration with pharmaceutical AbbVie built on developing therapies, primarily for cancer, including solid tumors.
The U.S. Food and Drug Administration has approved a plant-derived cannabis medicine, benefitting Carlsbad’s Greenwich Biosciences, the U.S. subsidiary of United Kingdom-based GW Pharmaceuticals.
BIOTECH: It’s Still Low For Medtech Peers; Co. Inks International Deals
This comeback story appears to have legs.
William Welch has resigned as CEO and director of San Diego biotech Trovagene, citing personal reasons. The resignation is effective immediately.
Tandem Diabetes Care won U.S. Food and Drug Administration approval for an automated insulin technology designed to reduce the frequency and duration of low blood sugar events.